Revolution Medicines (NASDAQ:RVMD) COO Margaret Horn Sells 4,583 Shares

Revolution Medicines, Inc. (NASDAQ:RVMD) COO Margaret Horn sold 4,583 shares of the stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $99.48, for a total value of $455,916.84. Following the sale, the chief operating officer owned 157,570 shares of the company’s stock, valued at $15,675,063.60. This represents a 2.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Revolution Medicines Price Performance

Shares of Revolution Medicines stock opened at $99.29 on Friday. The company has a debt-to-equity ratio of 0.16, a current ratio of 7.14 and a quick ratio of 7.14. The business’s 50 day simple moving average is $103.42 and its two-hundred day simple moving average is $76.40. The stock has a market capitalization of $19.68 billion, a P/E ratio of -16.80 and a beta of 0.99. Revolution Medicines, Inc. has a one year low of $29.17 and a one year high of $124.49.

Revolution Medicines (NASDAQ:RVMD) last released its quarterly earnings data on Wednesday, February 25th. The company reported ($1.86) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.56) by ($0.30). During the same quarter in the previous year, the firm earned ($1.12) earnings per share. Analysts forecast that Revolution Medicines, Inc. will post -3.49 EPS for the current year.

More Revolution Medicines News

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: Large institutional buys and heavy institutional ownership (General Atlantic, Norges Bank, Avoro, UBS, Polar Capital and others acquired meaningful stakes or added materially), signaling strong institutional conviction that can support the stock. MarketBeat Institutional/Insider Summary
• Positive Sentiment: Analyst coverage is largely bullish — multiple recent upgrades/initiations (Evercore, Jefferies, UBS, Benchmark) and a consensus “Buy” bias among analysts, which can underpin buying interest and price support. Analyst Coverage Summary
• Neutral Sentiment: Company profile and pipeline: clinical-stage biotech focused on RAS-pathway therapies (RMC-4630, RMC-6291, RMC-6236). Positive long-term potential but clinical/readout risk remains — typical for development-stage biotechs. Company Profile
• Neutral Sentiment: Recent quarterly report (Feb. 25) showed a wider loss (EPS -$1.86) and missed estimates — a reminder of ongoing cash burn and execution risk; analysts expect negative FY EPS. Earnings Summary
• Negative Sentiment: Several senior insiders sold shares on Mar. 17 (large disclosed Form 4s). Mark A. Goldsmith sold 12,871 shares (~$1.28M). SEC filing: Goldsmith SEC Filing
• Negative Sentiment: COO Margaret A. Horn sold 4,583 shares (~$456K). SEC filing: Horn SEC Filing
• Negative Sentiment: Stephen M. Kelsey sold 4,302 shares (~$428K). SEC filing: Kelsey SEC Filing
• Negative Sentiment: CFO Jack Anders sold 2,753 shares (~$274K). SEC filing: Anders SEC Filing
• Negative Sentiment: Insiders Xiaolin Wang and Lin Wei also sold smaller stakes (2,010 and 2,073 shares). SEC filings: Wang SEC Filing · Wei SEC Filing

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in RVMD. Nextech Invest Ltd. raised its holdings in Revolution Medicines by 20.7% in the 4th quarter. Nextech Invest Ltd. now owns 7,601,087 shares of the company’s stock worth $332,472,000 after purchasing an additional 1,304,347 shares in the last quarter. Millennium Management LLC increased its position in shares of Revolution Medicines by 681.8% during the first quarter. Millennium Management LLC now owns 156,353 shares of the company’s stock valued at $5,529,000 after buying an additional 136,353 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Revolution Medicines by 14.2% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 300,196 shares of the company’s stock valued at $10,615,000 after buying an additional 37,345 shares during the period. PNC Financial Services Group Inc. raised its stake in Revolution Medicines by 70.1% in the second quarter. PNC Financial Services Group Inc. now owns 7,695 shares of the company’s stock worth $283,000 after buying an additional 3,171 shares in the last quarter. Finally, Police & Firemen s Retirement System of New Jersey raised its stake in Revolution Medicines by 79.0% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 65,597 shares of the company’s stock worth $2,413,000 after buying an additional 28,954 shares in the last quarter. 94.34% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on RVMD. UBS Group began coverage on shares of Revolution Medicines in a report on Friday, February 27th. They issued a “buy” rating on the stock. Benchmark reaffirmed an “overweight” rating on shares of Revolution Medicines in a research note on Tuesday, February 17th. Evercore upgraded shares of Revolution Medicines to a “strong-buy” rating in a report on Wednesday, February 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of Revolution Medicines in a research note on Thursday, January 22nd. Finally, Jefferies Financial Group assumed coverage on Revolution Medicines in a report on Monday. They set a “buy” rating on the stock. Four investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Revolution Medicines currently has a consensus rating of “Buy” and an average target price of $78.94.

About Revolution Medicines

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.